New oral treatment challenges standard therapy for rare blood disorder
NCT ID NCT06593938
Summary
This study tested whether HRS-5965 capsules work as well as the standard treatment (eculizumab) for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The 24-week trial involved 76 patients who had not previously received complement inhibitor therapy. Researchers measured whether the new treatment could help patients maintain higher hemoglobin levels without needing blood transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100730, China
-
The Blood Disease Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.